Press Releases

Featured Press Releases

BIO Statement on December 2025 ACIP Meeting

WASHINGTON, D.C. – Phyllis Arthur, Executive Vice President and Head of Health Policy and Programs of the Biotechnology Innovation Organization (BIO) released the following statement on the December 2025 ACIP meeting.“For decades, the CDC’s Advisory…

Learn more

BIO Statement on the Retirement of Richard Pazdur…

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on reports of the retirement of Richard Pazdur from the US FDA.“Dr. Pazdur has dedicated decades of his career…

Learn more

BIO Statement on House Passage of Mikaela Naylon…

WASHINGTON, D.C. – The Biotechnology Innovation Organization (BIO) released the following statement on today’s passage of the Mikaela Naylon Give Kids a Chance Act in the House of Representatives.“The unanimous House passage of the Mikaela Naylon…

Learn more

Registration Now Open for the 14th Annual BIO World Congress on Industrial Biotechnology

February 8, 2017

BIO announced registration and housing are now open for the 2017 World Congress on Industrial Biotechnology. The conference will be held July 23-26, 2017 at the Palais des congrès de Montréal in Montréal,…

BIO Statement on President Trump’s Comments Supporting Biopharmaceutical Competition and Innovation

January 31, 2017

Washington, DC (January 31, 2017) – BIO issued the following statement regarding President Trump’s comments today supporting biopharmaceutical innovation:

BIO Statement on USDA and FDA Actions related to Pre-market Regulatory Oversight of Plant and Animal Organisms

January 18, 2017

The U.S. Department of Agriculture (USDA) and the U.S. Food and Drug Administration (FDA) published today four documents related to the pre-market regulatory oversight of a variety of biology-based agricultural tools, including genetically…

BIO’s Jim Greenwood Meets with India’s PM Modi

January 13, 2017

Delivers Message: India Must Protects Innovators’ Work Product

BIO Statement on Proposed Maryland Drug Pricing Legislation

January 10, 2017

BIO's statement regarding proposed drug pricing legislation within the Maryland Senate.

BIO CEO & Investor Conference Programming Announced

December 15, 2016

BIO announced programming for the 19th annual BIO CEO & Investor Conference. Held February 13-14 at the Waldorf Astoria in New York, the annual conference provides an environment for investors, analysts, industry executives and others to…

BIO Applauds Senate Passage of the 21st Century Cures Act

December 7, 2016

Washington, DC (December 7, 2016) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the 21st Century Cures Act by the U.S. Senate:

BIO Applauds House Passage of the 21st Century Cures Act

November 30, 2016

Washington, DC (November 30, 2016) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the 21st Century Cures Act by the U.S. House of Representatives:

BIO Responds to GAO Report Declaring RFS Will Not Meet Goals

November 29, 2016

BIO responds to GAO's latest report on the Renewable Fuel Standard (RFS), “Renewable Fuel Standard, Program Unlikely to Meet its Targets for Reducing Greenhouse Gas Emissions.” GAO correctly concludes the technology is available for advance biofuels…

BIO Welcomes EPA’s Final 2017 Renewable Fuel Standards

November 23, 2016

The Environmental Protection Agency’s final Renewable Fuel Standards for 2017 and biomass-based diesel volume for 2018 appear to put the program back on track and will provide considerable additional certainty for investors in advanced and…

Daily News You Can’t Afford to Miss

Read it in under 3 minutes!

The Good Day BIO newsletter is the only daily newsletter at the intersection of biotech, politics, and policy.